Highest-materiality recent filing
Merger closed July 21, 2026; shareholders received $13.25 per share in cash.
Cross Country Healthcare stockholders approve merger to go private; expected Q3 2026 close
Proposal to adopt merger agreement approved: 23,356,105 for, 12,309 against, 10,439 abstentions.
Cross Country Healthcare sets July 16 special meeting; supplements proxy after merger lawsuits
Special meeting to approve merger with KL Criss Cross Intermediate set for July 16, 2026; record date June 12.
HSR Act waiting period for the merger and Locums Transaction expired June 22, 2026, satisfying a major condition.
Cross Country Healthcare to be acquired by Knox Lane for $13.25/share in $437M all-cash deal
Deal valued at ~$437M, with stockholders receiving $13.25 per share in cash.
Cross Country Healthcare Q1 2026 revenue down 18% YoY, net loss widens to $4.3M
Revenue $241.1M, down 18% YoY; gross profit margin 19.7%, down 30 bps.
Cross Country Healthcare schedules Q1 2026 earnings call for May 7
Earnings call on May 7, 2026 at 5:00 PM ET after market close.
Cross Country Healthcare appoints Amiee Hawkins as COO effective March 28
Hawkins, previously Chief Solutions & Operations Officer, promoted to COO.
Cross Country Healthcare CIO Phil Noe departs; receives $205,975 severance, consulting role
Phil Noe ceased as Chief Information Officer effective March 10, 2026.
Cross Country Healthcare appoints Marvin Veizaga as CAO; James Redd and Phil Noe depart
James V. Redd III ceases as SVP & Chief Accounting Officer effective March 10, 2026; no dispute with company.
Cross Country Healthcare Q4 2025 revenue down 24% YoY; net loss of $82.9M
Revenue $236.8M in Q4 2025, down 24% YoY; full-year revenue $1.054B, down 22%.
Cross Country Healthcare to attend two investor conferences in March 2026
Truist Securities Virtual Human Capital Conference March 12-13, one-on-one March 12.
Cross Country Healthcare schedules Q4/FY 2025 earnings call for March 4, 2026
Earnings call on Wednesday, March 4, 2026 at 5:00 PM ET.
Cross Country Healthcare sets 2026 annual meeting for May 11, updates proposal deadlines
2026 annual meeting will be held virtually on May 11, 2026.
Cross Country Healthcare discloses CEO Kevin Clark's employment terms: $950K salary, bonus, equity
Base salary $950K; 2026 target bonus 100% of base (max 180%), rising to 125% target from 2027.
Cross Country CEO Martins departs; co-founder Clark returns as CEO after Aya deal termination
CEO John Martins separated effective Dec 14, 2025; receives severance of 2-year base salary ($875K) plus average bonus.
All 7 director nominees elected with strong support; Gale Fitzgerald received the most against votes at 2,651,031.
Cross Country Healthcare merger with Aya Healthcare terminated; to receive $20M fee; starts buybacks
Merger agreement with Aya Healthcare terminated effective Dec 4, 2025 after failing to close by Dec 3, 2025 end date.
Cross Country Healthcare Q3 revenue $250M, down 21% YoY; net loss $4.8M
Revenue $250.1M, down 21% YoY and 9% sequentially; gross margin 20.4% flat.
Cross Country Healthcare sets annual meeting for Dec 9, conditional on Aya merger not closing first
Annual Meeting scheduled for virtual-only on December 9, 2025; proxy statement available on or before Oct 30.
Cross Country Healthcare extends merger deadline to Dec 3, 2025; FTC compliance certified
Merger end date automatically extended from Sept 3, 2025 to Dec 3, 2025 per the Merger Agreement.
Cross Country Healthcare Q2 revenue down 19% YoY, net loss of $6.7M, negative adjusted EPS
Revenue $274.1M, down 19% YoY; gross margin 20.4%, down 40 bps.
Cross Country Q1 revenue down 23% YoY to $293.4M; adjusted EPS $0.06
Revenue $293.4M, down 23% YoY; net loss $490K ($0.02 loss per share).
Cross Country Healthcare reports Q4 2024 revenue down 25% YoY, net loss of $3.8M
Q4 2024 revenue $309.9M, down 25% YoY and 2% sequentially.
Stockholders approve Aya Healthcare acquisition; merger expected H2 2025
Over 78% of shares voted; 25.66M votes for Merger Agreement, 11K against.
Cross Country Healthcare receives FTC Second Request for Aya merger; close expected H2 2025
FTC issued Second Request under HSR Act, extending waiting period until 30 days after substantial compliance by both parties.
Aya Healthcare to acquire Cross Country Healthcare for $18.61/share (~$615M all-cash)
Stockholders receive $18.61 per share in cash, a 67% premium to Dec 3 closing price.
Cross Country Healthcare Q3 revenue down 29% YoY to $315M; EPS $0.08
Revenue of $315.1M fell 29% YoY; gross margin 20.4%, down 160 bps.
Cross Country Healthcare to attend UBS Global Healthcare Conference in November 2024
Participation in UBS Global Healthcare Conference Nov 11-14 at Terranea Resort, CA.
Cross Country Healthcare schedules Q3 2024 earnings call for Nov 6, 2024
Earnings call on Wednesday, November 6, 2024 at 5:00 p.m. ET.
Cross Country Healthcare to attend two investor conferences in September 2024
Morgan Stanley 22nd Annual Global Healthcare Conference: Sept 4-6, NYC; John Martins and Josh Vogel on Sept 5.
Cross Country Q2 revenue down 37% YoY to $339.8M; net loss of $16.0M
Revenue $339.8M, down 37% YoY and 10% sequentially; gross margin 20.8% (-200 bps YoY).
Cross Country Healthcare amends ABL credit agreement to ease share repurchase restrictions
Amendment No. 7 to ABL Credit Agreement with Wells Fargo, dated July 29, 2024, relaxes share repurchase covenant.
Cross Country Healthcare sets Q2 2024 earnings call for July 31
Conference call to discuss Q2 2024 results at 5:00 p.m. ET on July 31, 2024.
Cross Country Healthcare to participate in Citizens JMP conference on June 20, 2024
CEO John Martins and VP IR Josh Vogel will hold one-on-one investor meetings at the Boston Harbor Hotel.
Stockholders approve 2024 Omnibus Incentive Plan adding 2.4M shares
Plan replaces 2020 Omnibus Incentive Plan; 2,400,000 new shares authorized for equity awards.
All eight director nominees elected with majority votes; Gale Fitzgerald received ~25.1M for vs ~4.5M against.
Cross Country Healthcare to attend William Blair and Jefferies healthcare conferences in June 2024
William Blair Growth Stock Conference: June 4-6 in Chicago; CEO John Martins and IR Josh Vogel attending.
Cross Country Healthcare customer files Chapter 11; expects $20M bad debt charge in Q2 2024
Customer filed Chapter 11 bankruptcy on May 6, 2024.
Cross Country Healthcare to attend Benchmark's Healthcare House Call Investor Conference
Conference: Benchmark's Healthcare House Call Virtual One-on-One, May 21-22, 2024.
Cross Country Healthcare Q1 revenue down 39% YoY to $379M; net income falls 91%
Revenue $379.2M, down 39% YoY and 8% sequentially.
Cross Country Healthcare announces Q1 2024 earnings call date: May 1, 2024
Conference call to discuss Q1 2024 results on Wednesday, May 1, 2024 at 5:00 PM ET.
Cross Country Healthcare to attend Oppenheimer healthcare conference on March 12, 2024
William J. Burns (CFO) and Josh Vogel (VP IR) will hold virtual one-on-one investor meetings.
Cross Country Healthcare Q4 net income drops 77% on 34% revenue decline
Q4 2023 revenue $414M, down 34% YoY and 6% sequentially; full year revenue $2.02B, down 28%.
Cross Country Healthcare CCO Daniel J. White to depart March 31, 2024
Chief Commercial Officer Daniel J. White will leave the company on March 31, 2024 under a separation agreement.
Cross Country Healthcare sets Q4 2023 earnings call for Feb 21 after market close
Earnings release and conference call scheduled for Wednesday, February 21, 2024 at 5:00 p.m. ET.
Revenue of $442.3M, down 30% from Q3 2022 and 18% from Q2 2023.
Cross Country Healthcare announces Q3 2023 earnings call date; no results disclosed
Earnings call scheduled for November 1, 2023 at 5:00 p.m. ET.
Cross Country's ABL covenant becomes springing, tied to excess availability thresholds
Amendment No. 6 changes fixed charge coverage ratio from maintenance to springing covenant triggered when excess availability falls below greater of 15% of loan cap or $24M.
Cross Country Healthcare to attend Barrington Research conference; no formal presentation
CFO William Burns and VP Josh Vogel will hold one-on-one meetings at the conference on September 14, 2023.
On February 14, 2024, Cross Country Healthcare, Inc. (the “Company”) entered into a separation agreement (the “Agreement”) with Daniel J. White, Chief Commercial Officer. Under the Agreement, Mr. White will depart the Company on March 31, 2024 (the “Effective Date”).
On January 3, 2023 the Board of Directors (the “Board”) of Cross Country Healthcare, Inc. (the “Company”) appointed Dwayne L. Allen as a director of the Board (the “Appointment”), with such Appointment to be effective immediately.
On November 16, 2022 the Board of Directors (the “Board”) of Cross Country Healthcare, Inc. (the “Company”) appointed Venkat Bhamidipati as a director of the Board (the “Appointment”).
James V. Redd III has been promoted to Senior Vice President and Chief Accounting Officer
On September 19, 2022 (the “Effective Date”), Cross Country Healthcare, Inc. (the “Company”) terminated the employment of Buffy S. White, Group President, Workforce Solutions of the Company, without cause and effective immediately.
On April 5, 2022, Daniel J. White became employed by Cross Country Healthcare, Inc. (“Cross Country” or the “Company”) as its Chief Commercial Officer.
will be appointed as a director of the Company (the “Appointment”)
Kevin C. Clark, Co-Founder and Chief Executive Officer (“CEO”) of the Company, will retire and transition from his current role as President and CEO of the Company to Chairman of the Board (the “Transition”).
John A. Martins, the Company’s current Group President, Delivery, will be promoted to President and CEO (the “Promotion”)
Max materiality 0.95 · Median 0.53 · Most common event other